3Dallal RM, Lotze MT.The dendritic cell and human cancer vaccines [J]. Curr Opin Immunol, 2000,12:553 - 558.
4Inaba K, Inaba M, Naito M, et al. Dendritic cell progenitors phagocytose particulates, including bacillus Calmette - Guerin organisms, and sensitize mice to mycobacterial antigens in vivo[J]. J Exp Med 1993,178(2) :479 - 488.
5Sallusto F, celia M, Danieli C, et al. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histceompatibility complex class Ⅱ compartment: dowaregulation by cytokines and bacterial products[J] .J Exp Med 1995,182(2):389- 400.
6Sallusto F, Lanzaveechia A.Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony- stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha[J]. J Exp Med 1994,179(4):1109- 1118.
7Mailliard RB, Dallal RM, Son YI, et al. Dendritic cells promote T- cell survival or death depending upon their maturation state and presentation of antigen[ J]. Immunol Invest, 2000 May, 29(2) : 177 - 185.
8Ranieri E, Kierstead LS, Zarour H, et al. Dendritic cell/peptide cancer vaccines: clinical responsiveness and epitope spreading [J].Immanol Invest, 2000 May
9Mule JJ. Tumor vaccine strategies that employ dendritic cells and tumor lysates:experimental and clinical studies[J]. Immunol Invest 2000,29(2) : 127 - 129.
10Kugler A, Stuhler G, Walden P, et al. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell - dendritic cell hybrids[J] .Nat Med.2000 Mar,6(3) :332 - 336.
